ACM
Altium Capital Management Portfolio holdings
AUM
$34.4M
This Quarter Return
+44.08%
1 Year Return
-2.5%
3 Year Return
+357.21%
5 Year Return
–
10 Year Return
–
AUM
$128M
AUM Growth
+$128M
(-24%)
Cap. Flow
-$42.9M
Cap. Flow
% of AUM
-33.52%
Top 10 Holdings %
Top 10 Hldgs %
60.63%
Holding
108
New
16
Increased
5
Reduced
5
Closed
41
Top Buys
| 1 |
IMGN
Immunogen Inc
IMGN
|
$9.15M |
| 2 |
Xenon Pharmaceuticals
XENE
|
$8.78M |
| 3 |
GRI Bio
GRI
|
$5.01M |
| 4 |
MoonLake Immunotherapeutics
MLTX
|
$4.49M |
| 5 |
Harmony Biosciences
HRMY
|
$4.22M |
Top Sells
| 1 |
BLU
BELLUS Health Inc.
BLU
|
$8.15M |
| 2 |
Arcellx
ACLX
|
$4.62M |
| 3 |
AVDL
Avadel Pharmaceuticals
AVDL
|
$4.58M |
| 4 |
Glaukos
GKOS
|
$4.56M |
| 5 |
Penumbra
PEN
|
$4.46M |
Sector Composition
| 1 | Healthcare | 95.31% |
| 2 | Financials | 1.22% |
| 3 | Technology | 1.22% |
| 4 | Communication Services | 0.46% |
| 5 | Materials | 0.21% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
KDNY
1
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
| $11.7M | 8.87% | 305,000 | – | – |
|
2
Astria Therapeutics
ATXS
$349M
| $11.2M | 8.49% | 1,347,088 | – | – |
|
|
IMGN
3
DELISTED
Immunogen Inc
IMGN
| $9.15M | 6.93% | +485,000 | New | +$9.15M |
|
4
ADMA Biologics
ADMA
$4.12B
| $8.78M | 6.65% | 2,380,000 -490,000 | -17% | -$1.81M |
|
|
5
Xenon Pharmaceuticals
XENE
$2.98B
| $8.78M | 6.64% | +228,000 | New | +$8.78M |
|
|
CBAY
6
DELISTED
Cymabay Therapeutics
CBAY
| $7.32M | 5.54% | 668,702 +48,702 | +8% | +$533K |
|
7
Xtant Medical Holdings
XTNT
$83.3M
| $5.79M | 4.38% | 6,227,559 | – | – |
|
|
8
Harmony Biosciences
HRMY
$2.12B
| $5.27M | 3.99% | 149,889 +119,889 | +400% | +$4.22M |
|
|
9
GRI Bio
GRI
$3.5M
| $5.01M | 3.79% | +1,179,286 | New | +$5.01M |
|
|
10
MoonLake Immunotherapeutics
MLTX
$3.54B
| $4.49M | 3.4% | +88,000 | New | +$4.49M |
|
|
RETA
11
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
| $4.23M | 3.2% | 41,485 +6,485 | +19% | +$661K |
|
12
Amylyx Pharmaceuticals
AMLX
$836M
| $3.99M | 3.02% | 185,000 | – | – |
|
13
Jasper Therapeutics
JSPR
$45.5M
| $3.93M | 2.97% | +2,868,000 | New | +$3.93M |
|
|
ICPT
14
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
| $3.57M | 2.7% | +323,000 | New | +$3.57M |
|
15
Sarepta Therapeutics
SRPT
$1.78B
| $3.21M | 2.43% | +28,000 | New | +$3.21M |
|
16
Replimune Group
REPL
$422M
| $3.02M | 2.28% | 130,000 -18,000 | -12% | -$418K |
|
17
Phathom Pharmaceuticals
PHAT
$864M
| $2.97M | 2.25% | +207,432 | New | +$2.97M |
|
18
Axsome Therapeutics
AXSM
$6.05B
| $2.87M | 2.18% | +40,000 | New | +$2.87M |
|
19
Olema Pharmaceuticals
OLMA
$375M
| $2.8M | 2.12% | +310,000 | New | +$2.8M |
|
20
Cogent Biosciences
COGT
$1.69B
| $2.78M | 2.11% | +235,000 | New | +$2.78M |
|
21
Crinetics Pharmaceuticals
CRNX
$2.92B
| $2.43M | 1.84% | 135,000 +35,000 | +35% | +$631K |
|
22
Vera Therapeutics
VERA
$1.38B
| $1.93M | 1.46% | 120,000 -166,000 | -58% | -$2.66M |
|
23
Dyne Therapeutics
DYN
$1.92B
| $1.74M | 1.32% | 155,000 | – | – |
|
24
Praxis Precision Medicines
PRAX
$958M
| $1.64M | 1.24% | +1,425,000 | New | +$1.64M |
|
25
Karyopharm Therapeutics
KPTI
$61.7M
| $1.32M | 1% | 740,000 +234,219 | +46% | +$419K |
|